author-photo

Eleonora Restuccia

Hoffmann-La Roche

35

Papers

326

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (15)
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

2021 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (21)
Abstract PS10-20: Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (3)